Replies to post #238086 on Biotech Values

[DewDiligence]

BMY—FDC of Opdivo/Relatimab—(anti-LAG-3)—has 3/19/22 PDUFA date for 1L-melanoma (with FDA priority review):

https://finance.yahoo.com/news/u-food-drug-administration-accepts-105900488.html